Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma...
Gespeichert in:
Veröffentlicht in: | Journal of Neural Transmission 2009-12, Vol.116 (12), p.1591-1599 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1599 |
---|---|
container_issue | 12 |
container_start_page | 1591 |
container_title | Journal of Neural Transmission |
container_volume | 116 |
creator | Cozzi, Nicholas V. Gopalakrishnan, Anupama Anderson, Lyndsey L. Feih, Joel T. Shulgin, Alexander T. Daley, Paul F. Ruoho, Arnold E. |
description | N,N
-dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related
N,N
-dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT,
N
-methyl-
N
-isopropyltryptamine (MIPT),
N,N
-dipropyltryptamine (DPT), and
N,N
-diisopropyltryptamine. We then tested the abilities of these
N,N
-dialkyltryptamines to inhibit [
3
H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [
3
H]paroxetine binding to the SERT and [
3
H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [
3
H]5-HT transport at the SERT with
K
I
values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [
3
H]5-HT transport with
K
I
values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [
3
H]paroxetine binding to SERT and of [
3
H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters. |
doi_str_mv | 10.1007/s00702-009-0308-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21267762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733589521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhYMoTjv6AG4kuNBVaVKpys9SZvyDATe6Dknq1lTGqqRNUoP9Lj6saaqhRdDNDdx85xwuB6HnlLyhhIi3uQ7SNoSohjAiG_kA7WjH-oZ2nD1Eu7okjep5d4Ge5HxHCKFUyMfogirRc8bpDv269guU6TCXdNgXs_gA2IQBxzJBwpOZ59X5EG8heIfPTMbwc_LWF5xXm0syBbCFydz7mLApuKpxhhRLDD7gtaq-Q5WbkPcxlep8zDhC95C9mwEvMcQt_Q_qKXo0mjnDs9N7ib59eP_16lNz8-Xj56t3N43rOlUa6KDtpRFkUNJ14KQV0oA1ijErWkMGaodxpG4Ug5HjIFzPpbKjkYxaZYVil-j15rtP8ccKuejFZwfzbALENWvBWC9V39JKvvov2dKWC8HbCr78C7yLawr1isoIyQnlokJ0g1yKOScY9T75xaSDpkQfG9Zbw7o2rI8Na1k1L07Gq11gOCtOlVag3YBcv8ItpHPyv11_AyO5tvI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217860167</pqid></control><display><type>article</type><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><source>MEDLINE</source><source>Springer LINK 全文期刊数据库</source><creator>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</creator><creatorcontrib>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</creatorcontrib><description>N,N
-dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related
N,N
-dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT,
N
-methyl-
N
-isopropyltryptamine (MIPT),
N,N
-dipropyltryptamine (DPT), and
N,N
-diisopropyltryptamine. We then tested the abilities of these
N,N
-dialkyltryptamines to inhibit [
3
H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [
3
H]paroxetine binding to the SERT and [
3
H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [
3
H]5-HT transport at the SERT with
K
I
values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [
3
H]5-HT transport with
K
I
values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [
3
H]paroxetine binding to SERT and of [
3
H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/s00702-009-0308-8</identifier><identifier>PMID: 19756361</identifier><identifier>CODEN: JNTRF3</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Animals ; Basic Neurosciences ; Blood Platelets - chemistry ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; Cell Line ; Genetics and Immunology - Original Article ; Hallucinogens - chemistry ; Hallucinogens - metabolism ; Hallucinogens - pharmacology ; Humans ; Medicine ; Medicine & Public Health ; N,N-Dimethyltryptamine - chemistry ; N,N-Dimethyltryptamine - metabolism ; N,N-Dimethyltryptamine - pharmacology ; Neurology ; Neurosciences ; Paroxetine - chemistry ; Paroxetine - metabolism ; Paroxetine - pharmacology ; Psychiatry ; Rats ; Serotonin - chemistry ; Serotonin - metabolism ; Serotonin Plasma Membrane Transport Proteins - chemistry ; Serotonin Plasma Membrane Transport Proteins - metabolism ; Serotonin Uptake Inhibitors - chemistry ; Serotonin Uptake Inhibitors - metabolism ; Serotonin Uptake Inhibitors - pharmacology ; Spodoptera ; Tetrabenazine - analogs & derivatives ; Tetrabenazine - chemistry ; Tetrabenazine - metabolism ; Tetrabenazine - pharmacology ; Tritium ; Tryptamines - chemistry ; Tryptamines - metabolism ; Tryptamines - pharmacology ; Vesicular Monoamine Transport Proteins - chemistry ; Vesicular Monoamine Transport Proteins - metabolism</subject><ispartof>Journal of Neural Transmission, 2009-12, Vol.116 (12), p.1591-1599</ispartof><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</citedby><cites>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00702-009-0308-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00702-009-0308-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19756361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Gopalakrishnan, Anupama</creatorcontrib><creatorcontrib>Anderson, Lyndsey L.</creatorcontrib><creatorcontrib>Feih, Joel T.</creatorcontrib><creatorcontrib>Shulgin, Alexander T.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><creatorcontrib>Ruoho, Arnold E.</creatorcontrib><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm</addtitle><addtitle>J Neural Transm (Vienna)</addtitle><description>N,N
-dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related
N,N
-dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT,
N
-methyl-
N
-isopropyltryptamine (MIPT),
N,N
-dipropyltryptamine (DPT), and
N,N
-diisopropyltryptamine. We then tested the abilities of these
N,N
-dialkyltryptamines to inhibit [
3
H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [
3
H]paroxetine binding to the SERT and [
3
H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [
3
H]5-HT transport at the SERT with
K
I
values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [
3
H]5-HT transport with
K
I
values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [
3
H]paroxetine binding to SERT and of [
3
H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</description><subject>Animals</subject><subject>Basic Neurosciences</subject><subject>Blood Platelets - chemistry</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>Cell Line</subject><subject>Genetics and Immunology - Original Article</subject><subject>Hallucinogens - chemistry</subject><subject>Hallucinogens - metabolism</subject><subject>Hallucinogens - pharmacology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>N,N-Dimethyltryptamine - chemistry</subject><subject>N,N-Dimethyltryptamine - metabolism</subject><subject>N,N-Dimethyltryptamine - pharmacology</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Paroxetine - chemistry</subject><subject>Paroxetine - metabolism</subject><subject>Paroxetine - pharmacology</subject><subject>Psychiatry</subject><subject>Rats</subject><subject>Serotonin - chemistry</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Plasma Membrane Transport Proteins - chemistry</subject><subject>Serotonin Plasma Membrane Transport Proteins - metabolism</subject><subject>Serotonin Uptake Inhibitors - chemistry</subject><subject>Serotonin Uptake Inhibitors - metabolism</subject><subject>Serotonin Uptake Inhibitors - pharmacology</subject><subject>Spodoptera</subject><subject>Tetrabenazine - analogs & derivatives</subject><subject>Tetrabenazine - chemistry</subject><subject>Tetrabenazine - metabolism</subject><subject>Tetrabenazine - pharmacology</subject><subject>Tritium</subject><subject>Tryptamines - chemistry</subject><subject>Tryptamines - metabolism</subject><subject>Tryptamines - pharmacology</subject><subject>Vesicular Monoamine Transport Proteins - chemistry</subject><subject>Vesicular Monoamine Transport Proteins - metabolism</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEUhYMoTjv6AG4kuNBVaVKpys9SZvyDATe6Dknq1lTGqqRNUoP9Lj6saaqhRdDNDdx85xwuB6HnlLyhhIi3uQ7SNoSohjAiG_kA7WjH-oZ2nD1Eu7okjep5d4Ge5HxHCKFUyMfogirRc8bpDv269guU6TCXdNgXs_gA2IQBxzJBwpOZ59X5EG8heIfPTMbwc_LWF5xXm0syBbCFydz7mLApuKpxhhRLDD7gtaq-Q5WbkPcxlep8zDhC95C9mwEvMcQt_Q_qKXo0mjnDs9N7ib59eP_16lNz8-Xj56t3N43rOlUa6KDtpRFkUNJ14KQV0oA1ijErWkMGaodxpG4Ug5HjIFzPpbKjkYxaZYVil-j15rtP8ccKuejFZwfzbALENWvBWC9V39JKvvov2dKWC8HbCr78C7yLawr1isoIyQnlokJ0g1yKOScY9T75xaSDpkQfG9Zbw7o2rI8Na1k1L07Gq11gOCtOlVag3YBcv8ItpHPyv11_AyO5tvI</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Cozzi, Nicholas V.</creator><creator>Gopalakrishnan, Anupama</creator><creator>Anderson, Lyndsey L.</creator><creator>Feih, Joel T.</creator><creator>Shulgin, Alexander T.</creator><creator>Daley, Paul F.</creator><creator>Ruoho, Arnold E.</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><author>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Basic Neurosciences</topic><topic>Blood Platelets - chemistry</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>Cell Line</topic><topic>Genetics and Immunology - Original Article</topic><topic>Hallucinogens - chemistry</topic><topic>Hallucinogens - metabolism</topic><topic>Hallucinogens - pharmacology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>N,N-Dimethyltryptamine - chemistry</topic><topic>N,N-Dimethyltryptamine - metabolism</topic><topic>N,N-Dimethyltryptamine - pharmacology</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Paroxetine - chemistry</topic><topic>Paroxetine - metabolism</topic><topic>Paroxetine - pharmacology</topic><topic>Psychiatry</topic><topic>Rats</topic><topic>Serotonin - chemistry</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Plasma Membrane Transport Proteins - chemistry</topic><topic>Serotonin Plasma Membrane Transport Proteins - metabolism</topic><topic>Serotonin Uptake Inhibitors - chemistry</topic><topic>Serotonin Uptake Inhibitors - metabolism</topic><topic>Serotonin Uptake Inhibitors - pharmacology</topic><topic>Spodoptera</topic><topic>Tetrabenazine - analogs & derivatives</topic><topic>Tetrabenazine - chemistry</topic><topic>Tetrabenazine - metabolism</topic><topic>Tetrabenazine - pharmacology</topic><topic>Tritium</topic><topic>Tryptamines - chemistry</topic><topic>Tryptamines - metabolism</topic><topic>Tryptamines - pharmacology</topic><topic>Vesicular Monoamine Transport Proteins - chemistry</topic><topic>Vesicular Monoamine Transport Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Gopalakrishnan, Anupama</creatorcontrib><creatorcontrib>Anderson, Lyndsey L.</creatorcontrib><creatorcontrib>Feih, Joel T.</creatorcontrib><creatorcontrib>Shulgin, Alexander T.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><creatorcontrib>Ruoho, Arnold E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cozzi, Nicholas V.</au><au>Gopalakrishnan, Anupama</au><au>Anderson, Lyndsey L.</au><au>Feih, Joel T.</au><au>Shulgin, Alexander T.</au><au>Daley, Paul F.</au><au>Ruoho, Arnold E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</atitle><jtitle>Journal of Neural Transmission</jtitle><stitle>J Neural Transm</stitle><addtitle>J Neural Transm (Vienna)</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>116</volume><issue>12</issue><spage>1591</spage><epage>1599</epage><pages>1591-1599</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTRF3</coden><abstract>N,N
-dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related
N,N
-dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT,
N
-methyl-
N
-isopropyltryptamine (MIPT),
N,N
-dipropyltryptamine (DPT), and
N,N
-diisopropyltryptamine. We then tested the abilities of these
N,N
-dialkyltryptamines to inhibit [
3
H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [
3
H]paroxetine binding to the SERT and [
3
H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [
3
H]5-HT transport at the SERT with
K
I
values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [
3
H]5-HT transport with
K
I
values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [
3
H]paroxetine binding to SERT and of [
3
H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>19756361</pmid><doi>10.1007/s00702-009-0308-8</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0300-9564 |
ispartof | Journal of Neural Transmission, 2009-12, Vol.116 (12), p.1591-1599 |
issn | 0300-9564 1435-1463 |
language | eng |
recordid | cdi_proquest_miscellaneous_21267762 |
source | MEDLINE; Springer LINK 全文期刊数据库 |
subjects | Animals Basic Neurosciences Blood Platelets - chemistry Blood Platelets - drug effects Blood Platelets - metabolism Cell Line Genetics and Immunology - Original Article Hallucinogens - chemistry Hallucinogens - metabolism Hallucinogens - pharmacology Humans Medicine Medicine & Public Health N,N-Dimethyltryptamine - chemistry N,N-Dimethyltryptamine - metabolism N,N-Dimethyltryptamine - pharmacology Neurology Neurosciences Paroxetine - chemistry Paroxetine - metabolism Paroxetine - pharmacology Psychiatry Rats Serotonin - chemistry Serotonin - metabolism Serotonin Plasma Membrane Transport Proteins - chemistry Serotonin Plasma Membrane Transport Proteins - metabolism Serotonin Uptake Inhibitors - chemistry Serotonin Uptake Inhibitors - metabolism Serotonin Uptake Inhibitors - pharmacology Spodoptera Tetrabenazine - analogs & derivatives Tetrabenazine - chemistry Tetrabenazine - metabolism Tetrabenazine - pharmacology Tritium Tryptamines - chemistry Tryptamines - metabolism Tryptamines - pharmacology Vesicular Monoamine Transport Proteins - chemistry Vesicular Monoamine Transport Proteins - metabolism |
title | Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dimethyltryptamine%20and%20other%20hallucinogenic%20tryptamines%20exhibit%20substrate%20behavior%20at%20the%20serotonin%20uptake%20transporter%20and%20the%20vesicle%20monoamine%20transporter&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=Cozzi,%20Nicholas%20V.&rft.date=2009-12-01&rft.volume=116&rft.issue=12&rft.spage=1591&rft.epage=1599&rft.pages=1591-1599&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTRF3&rft_id=info:doi/10.1007/s00702-009-0308-8&rft_dat=%3Cproquest_cross%3E733589521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217860167&rft_id=info:pmid/19756361&rfr_iscdi=true |